Recent advances in targeted anti-vasculature therapy: The neuroblastoma model

Current Drug Targets

Volumn 10, Issue 10, 2009, Pages 1021-1027

  Pastorino, F ^a   Di Paolo, D ^a   Loi, M ^a   Becherini, P ^a   Caffa, I ^a   Zorzoli, A ^a   Marimpietri, D ^a   Carosio, R ^a   Perri, P ^a   Montaldo, P G ^a   Brignole, C ^a   Pagnan, G ^a   Ribatti, D ^b   Allen, T M ^c   Ponzoni, M ^a  

^a G GASLINI INSTITUTE   (Italy)

^b UNIVERSITY OF BARI   (Italy)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

Angiogenesis; Anti tumour drugs; Ligand mediated targeting; Liposomes; Neuroblastoma; Peptides; Phage display

Indexed keywords

ANGIOGENESIS INHIBITOR; ANGIOPOIETIN 1; ANGIOPOIETIN 2; ARGININE; ASPARAGINE; BASIC FIBROBLAST GROWTH FACTOR; DOXORUBICIN; FIBROBLAST GROWTH FACTOR 2; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; GLYCINE; INTERLEUKIN 8; LIPOSOME; LUCIFERASE; MICROSOMAL AMINOPEPTIDASE; OXYGEN; PLACENTAL GROWTH FACTOR; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR TARGETING AGENT; VASCULOTROPIN;

ADJUVANT THERAPY; ANGIOGENESIS; BIOLUMINESCENCE; CANCER CELL; CELL GROWTH; CELL PROLIFERATION; CELL SURVIVAL; CONTRAST ENHANCEMENT; DISEASE MODEL; DRUG TARGETING; ENDOTHELIUM CELL; IN VITRO STUDY; IN VIVO STUDY; INDIVIDUALIZATION; LUNG CANCER; MINIMAL RESIDUAL DISEASE; NANOMEDICINE; NEUROBLASTOMA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OUTCOME ASSESSMENT; OVARY CANCER; OXYGEN CONSUMPTION; PATIENT CARE; PHAGE DISPLAY; PROGNOSIS; REVIEW; TREATMENT OUTCOME; TUMOR GROWTH; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; DISEASE PROGRESSION; DRUG DELIVERY SYSTEMS; HUMANS; NEOVASCULARIZATION, PATHOLOGIC; NEUROBLASTOMA; PROGNOSIS;

EID: 70450205123     PISSN: 13894501     EISSN: None     Source Type: Journal    
DOI: 10.2174/138945009789577954     Document Type: Review

References (76)

1. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med 1995; 1: 27-31.
2. Risau W. Mechanisms of angiogenesis. Nature 1997; 386: 671-674
3. Ribatti D, Vacca A, Dammacco F. The role of the vascular phase in solid tumor growth: a historical review. Neoplasia 1999; 1: 293-302.
4. Carmeliet P. Angiogenesis in health and disease. Nat Med 2003; 9: 653-660
5. Murphy G, Nagase H. Progress in matrix metalloproteinase research. Mol Aspects Med 2008; 29: 290-308.
6. Goh PP, Sze DM, Roufogalis BD. Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets 2007; 7: 743-758
7. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996; 86: 353-364 (Pubitemid 26272076)
8. Murdoch C, Muthana M, Coffelt SB, Lewis CE. The role of myeloid cells in the promotion of tumour angiogenesis. Nat Rev Cancer 2008; 8: 618-631
9. Meitar D, Crawford SE, Rademaker AW, Cohn SL. Tumor angiogenesis correlates with metastatic disease, N-myc amplification, and poor outcome in human neuroblastoma. J Clin Oncol 1996; 14: 405-414 (Pubitemid 26051001)
10. Ara T, Fukuzawa M, Kusafuka T, Komoto Y, Oue T, Inoue M, et al. Immunohistochemical expression of MMP-2, MMP-9, and TIMP-2 in neuroblastoma: association with tumor progression and clinical outcome. J Pediatr Surg 1998; 33: 1272-1278 (Pubitemid 128713448)
11. Sakakibara M, Koizumi S, Saikawa Y, Wada H, Ichihara T, Sato H, et al. Membrane-type matrix metalloproteinase-1 expression and activation of gelatinase A as prognostic markers in advanced pediatric neuroblastoma. Cancer 1999; 85: 231-239 (Pubitemid 29031379)
12. Canete A, Navarro S, Bermudez J, Pellin A, Castel V, Llombart- Bosch A. Angiogenesis in neuroblastoma: relationship to survival and other prognostic factors in a cohort of neuroblastoma patients. J Clin Oncol 2000; 18: 27-34. (Pubitemid 30036333)
13. Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur GM, Himelstein BP. High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res 2000; 6: 1900-1908 (Pubitemid 30305088)
14. Ribatti D, Surico G, Vacca A, De Leonardis F, Lastilla G, Montaldo PG, et al. Angiogenesis extent and expression of matrix metalloproteinase-2 and -9 correlate with progression in human neuroblastoma. Life Sci 2001; 68: 1161-1168 (Pubitemid 32168042)
15. Kleinman NR, Lewandowska K, Culp LA. Tumour progression of human neuroblastoma cells tagged with a lacZ marker gene: earliest events at ectopic injection sites. Br J Cancer 1994; 69: 670-679 (Pubitemid 24112687)
16. Ribatti D, Alessandri G, Vacca A, Iurlaro M, Ponzoni M. Human neuroblastoma cells produce extracellular matrix-degrading enzymes, induce endothelial cell proliferation and are angiogenic in vivo. Int J Cancer 1998; 77: 449-454 (Pubitemid 28299883)
17. Schweigerer L, Breit S, Wenzel A, Tsunamoto K, Ludwig R, Schwab M. Augmented MYCN expression advances the malignant phenotype of human neuroblastoma cells: evidence for induction of autocrine growth factor activity. Cancer Res 1990; 50: 4411-4416 (Pubitemid 20225687)
18. Ribatti D, Raffaghello L, Pastorino F, Nico B, Brignole C, Vacca A, et al. In vivo angiogenic activity of neuroblastoma correlates with MYCN oncogene overexpression. Int J Cancer 2002; 102: 351-354
19. Erdreich-Epstein A, Shimada H, Groshen S, Liu M, Metelitsa LS, Kim KS, et al. Integrins alpha(v)beta3 and alpha(v)beta5 are expressed by endothelium of high-risk neuroblastoma and their inhibition is associated with increased endogenous ceramide. Cancer Res 2000; 60: 712-721
20. Huang D, Rutkowski JL, Brodeur GM, Chou PM, Kwiatkowski JL, Babbo A, et al. Schwann cell-conditioned medium inhibits angiogenesis. Cancer Res 2000; 60: 5966-5971 (Pubitemid 30839624)
21. Crawford SE, Stellmach V, Ranalli M, Huang X, Huang L, Volpert O, et al. Pigment epithelium-derived factor (PEDF) in neuroblastoma: a multifunctional mediator of Schwann cell antitumor activity. J Cell Sci 2001; 114: 4421-4428 (Pubitemid 34082862)
22. Chlenski A, Liu S, Crawford SE, Volpert OV, DeVries GH, Evangelista A, et al. SPARC is a key Schwannian-derived inhibitor controlling neuroblastoma tumor angiogenesis. Cancer Res 2002; 62: 7357-7363 (Pubitemid 36032697)
23. Leali D, Dell'Era P, Stabile H, Sennino B, Chambers AF, Naldini A, et al. Osteopontin (Eta-1) and fibroblast growth factor-2 cross-talk in angiogenesis. J Immunol 2003; 171: 1085-1093 (Pubitemid 36871426)
24. Takahashi F, Akutagawa S, Fukumoto H, Tsukiyama S, Ohe Y, Takahashi K, et al. Osteopontin induces angiogenesis of murine neuroblastoma cells in mice. Int J Cancer 2002; 98: 707-712 (Pubitemid 34225620)
25. Folkman J. How is blood vessel growth regulated in normal and neoplastic tissue? G.H.A. Clowes memorial Award lecture. Cancer Res 1986; 46: 467-473
26. Bergers G, Benjamin LE. Tumorigenesis and the angiogenic switch. Nat Rev Cancer 2003; 3: 401-410
27. Teicher BA. In: B. A. Teicher, Ellis, L. M., Antiangiogenic Agents in Cancer Therapy. Totowa, NJ,Humana Press. 2008; pp 133-153
28. Rossler J, Taylor M, Geoerger B, Farace F, Lagodny J, Peschka- Suss R, et al. Angiogenesis as a target in neuroblastoma. Eur J Cancer 2008; 44: 1645-1656
29. Kerbel RS. Tumor angiogenesis: past, present and the near future. Carcinogenesis 2000; 21: 505-515 (Pubitemid 30137936)
30. Ferrara N, Kerbel RS. Angiogenesis as a therapeutic target. Nature 2005; 438: 967-974
31. Kerbel RS. Molecular and physiologic mechanisms of drug resistance in cancer: an overview. Cancer Metastasis Rev 2001; 20: 1-2. (Pubitemid 34074672)
32. Rehman F, Rustin G. ASA404: update on drug development. Expert Opin Invest Drugs 2008; 17: 1547-1551
33. Siemann DW, Chaplin DJ, Walicke PA. A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P). Expert Opin Investig Drugs 2009; 18: 189-197
34. Cao Y. Tumor angiogenesis and molecular targets for therapy. Front Biosci 2009; 14: 3962-3973
35. Thorpe PE. Vascular targeting agents as cancer therapeutics. Clin Cancer Res 2004; 10: 415-427 (Pubitemid 38173977)
36. Gabizon A, Catane R, Uziely B, Kaufman B, Safra T, Cohen R, et al. Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes. Cancer Res 1994; 54: 987-992 (Pubitemid 24085451)
37. Allen TM. Ligand-targeted therapeutics in anticancer therapy. Nat Rev Cancer 2002; 2: 750-763
38. Pastorino F, Marimpietri D, Brignole C, Di Paolo D, Pagnan G, Daga A, et al. Ligand-targeted liposomal therapies of neuroblastoma. Curr Med Chem 2007; 14: 3070-3078
39. Jain RK. Molecular regulation of vessel maturation. Nat Med 2003; 9: 685-693
40. Nemeth JA, Nakada MT, Trikha M, Lang Z, Gordon MS, Jayson GC, et al. Alpha-v integrins as therapeutic targets in oncology. Cancer Invest 2007; 25: 632-646 (Pubitemid 350135743)
41. Rafii S, Lyden D. Cancer. A few to flip the angiogenic switch. Science 2008; 319: 163-164
42. Sato M, Arap W, Pasqualini R. Molecular targets on blood vessels for cancer therapies in clinical trials. Oncology (Williston Park) 2007; 21: 1346-52; discussion 54-5, 67, 70 passim.
43. Marchio S, Lahdenranta J, Schlingemann RO, Valdembri D, Wesseling P, Arap MA, et al. Aminopeptidase A is a functional target in angiogenic blood vessels. Cancer Cell 2004; 5: 151-162 (Pubitemid 38283801)
44. Sergeeva A, Kolonin MG, Molldrem JJ, Pasqualini R, Arap W. Display technologies: application for the discovery of drug and gene delivery agents. Adv Drug Deliv Rev 2006; 58: 1622-1654 (Pubitemid 44830148)
45. Pastorino F, Brignole C, Marimpietri D, Cilli M, Gambini C, Ribatti D, et al. Vascular damage and anti-angiogenic effects of tumor vessel-targeted liposomal chemotherapy. Cancer Res 2003; 63: 7400-7409 (Pubitemid 37413482)
46. Curnis F, Arrigoni G, Sacchi A, Fischetti L, Arap W, Pasqualini R, et al. Differential binding of drugs containing the NGR motif to CD13 isoforms in tumor vessels, epithelia, and myeloid cells. Cancer Res 2002; 62: 867-874 (Pubitemid 34126966)
47. O'Connell PJ, Gerkis V, d'Apice AJ. Variable O-glycosylation of CD13 (aminopeptidase N). J Biol Chem 1991; 266: 4593-4597 (Pubitemid 21909398)
48. Colombo G, Curnis F, De Mori GM, Gasparri A, Longoni C, Sacchi A, et al. Structure-activity relationships of linear and cyclic peptides containing the NGR tumor-homing motif. J Biol Chem 2002; 277: 47891-47897 (Pubitemid 36159317)
49. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, et al. Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 2000; 105: R15-24. (Pubitemid 30217701)
50. Jain RK. The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998; 4: 655-657 (Pubitemid 28274655)
51. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001; 7: 987-989
52. Huang X, Molema G, King S, Watkins L, Edgington TS, Thorpe PE. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997; 275: 547-550 (Pubitemid 27051913)
53. Pastorino F, Brignole C, Di Paolo D, Nico B, Pezzolo A, Marimpietri D, et al. Targeting liposomal chemotherapy via both tumor cell-specific and tumor vasculature-specific ligands potentiates therapeutic efficacy. Cancer Res 2006; 66: 10073-10082
54. Moss TJ, Reynolds CP, Sather HN, Romansky SG, Hammond GD, Seeger RC. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. N Engl J Med 1991; 324: 219-226
55. Fidler IJ. Modulation of the organ microenvironment for treatment of cancer metastasis. J Natl Cancer Inst 1995; 87: 1588-1592
56. Fidler IJ, Ellis LM. The implications of angiogenesis for the biology and therapy of cancer metastasis. Cell 1994; 79: 185-188 (Pubitemid 24324908)
57. Khanna C, Jaboin JJ, Drakos E, Tsokos M, Thiele CJ. Biologically relevant orthotopic neuroblastoma xenograft models: primary adrenal tumor growth and spontaneous distant metastasis. In Vivo 2002; 16: 77-85. (Pubitemid 34624816)
58. Pastorino F, Di Paolo D, Piccardi F, Nico B, Ribatti D, Daga A, et al. Enhanced antitumor efficacy of clinical-grade vasculature-targeted liposomal doxorubicin. Clin Cancer Res 2008; 14: 7320-7329
59. Garde SV, Forte AJ, Ge M, Lepekhin EA, Panchal CJ, Rabbani SA, et al. Binding and internalization of NGR-peptide-targeted liposomal doxorubicin (TVT-DOX) in CD13-expressing cells and its antitumor effects. Anticancer Drugs 2007; 18: 1189-1200 (Pubitemid 47480744)
60. Northfelt DW, Dezube BJ, Thommes JA, Levine R, Von Roenn JH, Dosik GM, et al. Efficacy of pegylated-liposomal doxorubicin in the treatment of AIDS-related Kaposi's sarcoma after failure of standard chemotherapy. J Clin Oncol 1997; 15: 653-659 (Pubitemid 27074235)
61. Gordon AN, Granai CO, Rose PG, Hainsworth J, Lopez A, Weissman C, et al. Phase II study of liposomal doxorubicin in platinum- and paclitaxel-refractory epithelial ovarian cancer. J Clin Oncol 2000; 18: 3093-3100 (Pubitemid 30677089)
62. Joseph JM, Gross N, Lassau N, Rouffiac V, Opolon P, Laudani L, et al. In vivo echographic evidence of tumoral vascularization and microenvironment interactions in metastatic orthotopic human neuroblastoma xenografts. Int J Cancer 2005; 113: 881-890
63. Condeelis J, Segall JE. Intravital imaging of cell movement in tumours. Nat Rev Cancer 2003; 3: 921-930 (Pubitemid 37500177)
64. Ponce AM, Viglianti BL, Yu D, Yarmolenko PS, Michelich CR, Woo J, et al. Magnetic resonance imaging of temperature-sensitive liposome release: drug dose painting and antitumor effects. J Natl Cancer Inst 2007; 99: 53-63.
65. Edinger M, Cao YA, Verneris MR, Bachmann MH, Contag CH, Negrin RS. Revealing lymphoma growth and the efficacy of immune cell therapies using in vivo bioluminescence imaging. Blood 2003; 101: 640-648
66. Armstrong SA, Kung AL, Mabon ME, Silverman LB, Stam RW, Den Boer ML, et al. Inhibition of FLT3 in MLL. Validation of a therapeutic target identified by gene expression based classification. Cancer Cell 2003; 3: 173-183
67. Elayadi AN, Samli KN, Prudkin L, Liu YH, Bian A, Xie XJ, et al. A peptide selected by biopanning identifies the integrin alphavbeta6 as a prognostic biomarker for nonsmall cell lung cancer. Cancer Res 2007; 67: 5889-5895 (Pubitemid 46985024)
68. Clamp AR, Jayson GC. In: B. A. Teicher, Ellis, L. M., Antiangiogenic Agents in Cancer Therapy. Totowa, NJ,Humana Press. 2008; pp 525-536
69. Torchilin VP. Recent advances with liposomes as pharmaceutical carriers. Nat Rev Drug Discov 2005; 4: 145-160
70. Gabizon A, Isacson R, Rosengarten O, Tzemach D, Shmeeda H, Sapir R. An open-label study to evaluate dose and cycle dependence of the pharmacokinetics of pegylated liposomal doxorubicin. Cancer Chemother Pharmacol 2008; 61: 695-702.
71. Allen TM, Cheng WW, Hare JI, Laginha KM. Pharmacokinetics and pharmacodynamics of lipidic nano-particles in cancer. Anticancer Agents Med Chem 2006; 6: 513-523 (Pubitemid 44697110)
72. Pastorino F, Mumbengegwi DR, Ribatti D, Ponzoni M, Allen TM. Increase of therapeutic effects by treating melanoma with targeted combinations of c-myc antisense and doxorubicin. J Control Release 2008; 126: 85-94.
73. Pastorino F, Brignole C, Marimpietri D, Sapra P, Moase EH, Allen TM, et al. Doxorubicin-loaded Fab' fragments of antidisialoganglioside immunoliposomes selectively inhibit the growth and dissemination of human neuroblastoma in nude mice. Cancer Res 2003; 63: 86-92. (Pubitemid 36070424)
74. Sapra P, Allen TM. Internalizing antibodies are necessary for improved therapeutic efficacy of antibody-targeted liposomal drugs. Cancer Res 2002; 62: 7190-7194 (Pubitemid 36025236)
75. Taatjes DJ, Koch TH. Nuclear targeting and retention of anthracycline antitumor drugs in sensitive and resistant tumor cells. Curr Med Chem 2001; 8: 15-29.
76. Pasqualini R, Ruoslahti E. Organ targeting in vivo using phage display peptide libraries. Nature 1996; 380: 364-366